Skip to Content

Multi-center open label single arm study of Yondelis (trabectedin) for subjects with locally advanced or metastic soft tissue sarcoma excluding leimyosarcoma and liposarcoma who have relapsed or are refractory to standard of care treatment. Phase III ET743-SAR-3002

Objective
A clinical trial of the investigational drug Yondelis, administered by intravenous infusion.
IRB Protocol Number
06-0026
Principal Investigator(s)
ANTHONY ELIAS

Cancer Trials

  • Sarcoma
Sponsor(s)
Johnson & Johnson Pharmaceutical R & D, LLC
Contact
TESSA MCSPADDEN at 720-848-0609
or TESSA.MCSPADDEN@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last approximately 4 months. A follow up period will consist of a clinic visit. // Eligibility criteria include but are not limited to patients 18 years or older with advanced soft tissue sarcoma.